Uromune Vaccine for Recurrent Urinary Tract Infections
Harley Street, London
Recurrent urinary tract infections (UTIs) are a common and distressing problem, particularly among women, significantly impacting quality of life. Traditional treatments often rely on repeated courses of antibiotics, which can lead to side effects, antibiotic resistance, and limited long-term effectiveness. As part of a modern, research-informed approach to managing this condition, Mr Nicholas Raison offers the Uromune (MV140) vaccine as a promising non-antibiotic treatment option for suitable patients.
What is Uromune?
Uromune is a sublingual (under the tongue) spray containing inactivated bacteria commonly responsible for UTIs, including Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris. This vaccine works by stimulating the body’s immune system to provide protection against future infections.
Clinical studies, including those reviewed by Mr Raison’s research team, have shown that Uromune can significantly reduce the frequency of UTIs with a favourable safety profile.
How is it administered?
The Uromune vaccine is taken daily as a spray under the tongue for a period of 3 months. This route of administration is needle-free and generally well tolerated. Patients can self-administer the spray at home, making the treatment convenient and non-disruptive to daily life.
Assessment and Follow-Up
Before starting the vaccine, a thorough assessment is required with Mr Raison or his specialist team to confirm the diagnosis and rule out other causes of recurrent infection. This may include urine testing, bladder imaging, and cystoscopy depending on individual circumstances. Following the initiation of Uromune, patients are monitored at intervals to assess symptom improvement, frequency of infections, and overall treatment effectiveness. Additional follow-up is arranged as needed to ensure optimal outcomes and manage any concerns.
Research and Innovation
Uromune is a relatively new treatment and is not currently offered routinely within the NHS. However, it represents an exciting advancement in the management of recurrent UTIs. In a recent systematic review and meta-analysis co-authored by Mr Raison and his research team, Uromune demonstrated excellent potential in reducing UTI recurrence compared to both placebo and antibiotic prophylaxis. While more high-quality trials are needed to fully validate its widespread use, early results are highly promising and support its use in carefully selected patients.
References
- Mak, Q., Greig, J., Dasgupta, P., Malde, S., & Raison, N. (2024). Bacterial Vaccines for the Management of Recurrent Urinary Tract Infections: A Systematic Review and Meta-analysis. European Urology Focus, 10(4), 761–769. https://doi.org/10.1016/j.euf.2024.04.002
- Mak, Q., Greig, J., Dasgupta, P., Malde, S., & Raison, N. (2024). Promising efficacy of UTI vaccines as an alternative to antibiotics. Nature Reviews Urology, 21, 701–702. https://doi.org/10.1038/s41585-024-00905-8
Mr Raison is available for private urology consultations, treatments, and surgical procedures at The London Clinic, Harley Street.